ALL INDIA INSTITUTE OF MEDICAL SCIENCES ANSARI NAGAR, NEW DELHI-110029

Stores Section (Main Hospital stores)

Dated: 06.09.2025

Ref. No.: 24/H/Tab. Ivosidenib 250mg/PAC/2025-26

Sub:-Purchase of "Tab. Ivosidenib 250mg" on proprietary basis Inviting comments thereon.

The Institute is in the process to purchase "Tab. Ivosidenib 250mg" for treatment of EHS patient Dr. Shalini Wig EHS No.R-7348 from M/s Servier India Private Limited. on proprietary basis. The proposal submitted by M/s Servier India Private Limited. and PAC Certifications are attached.

The above documents are being uploaded for open information to submit objections, comments, if any, from any manufacturer regarding proprietary nature of the item within issue of 15 days from the day of issue/uploading of the notification giving reference **Ref. No: 24/H/Tab. Ivosidenib 250mg/PAC/2025-26.** The comments should be received by office of Sr. Stores Officer (H), Main Hospital Store, at AIIMS New Delhi on or **before 20.09.2025 up to 12.30 P.M.** failing which it will be presumed that any other vendor is having no comment to offer and case will be decided on merit.

Manchar Arya Sr. Stores Officer (H)

Encl: Related documents enclosed.

PROPRIETORY ARTICLE CERTIFICATE (PAC)

(For Drugs/Medicines)

्रेक् नित्र बन्ना, एन.वी., डीएम /Dr. ATUL BATRA, MD., DM	(i)	The indented goods are manufactured by :
(iii) Item Name: 71B Sovo [Ivosidenib] (iii) Item Strength: 250 mg		Service Pharmaceutical LLCS
(iii) Item Strength 250.mg - 360 table [500 ng of x 6 month] (iv) Reasons/Justification which makes the requirement proprietary: 50lc manufacturers (PAC attacled) It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Aut 125, Addition Professor, Medical enology, Rea, Aliman 2000.		
(iii) Item Strength: 250 mg - 360 table	(ii)	Item Name:
(iii) Item Strength: 350 mg - 360 table		TIBSOVO [Ivosidenib]
(iv) Reasons/Justification which makes the requirement proprietary: Sole manufacturer (PAC attacked) It is certified that market survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Highest Additional Professor, Medical analysis, Ren, Aling, 2014-125, Additional Professor, Medical analysis, Ren, Aling, 2014-25, Additional Ren, Ren, Ren, Ren, Ren, Ren, Ren, Ren,		
It is certified that market survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi A. Addi A. Rodem, Medical encology, Ru, Aling and Talling and Modern.	(iii) Item Strength:
It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Hospital Proderm, Medical Oncology, Ren, Alim, 2017-125, Addings Proderm, Proder		
It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi And Poderm, Medical Oncology, RM, Aliman 2007, 2017, 2018, 300 JUL ATIM BATRA, MO.DM	(iv)	
It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi And Podern, Medical Oncology, RM, Alm, 2007, 2017, 2018, 2		301e manufacturer (PAC attacled)
It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi New Poderm, Medical Oncology, Ren, Alm., 2017-25, Addi New Br. Alm., 2017-25		· · · · · · · · · · · · · · · · · · ·
It is certified that marker survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi New Porferm, Medical Oncology, Rea, Alm, 2017, 25, 277, 277, 277, 277, 277, 277, 277		
It is certified that market survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi And Porferm, Medical Oncology, Ren, Alm, 2017,		
manufacturer is manufacturing similar/equivalent specifications which can fulfill the vital requirements of end user. Signature of TSEC With name, Designation, Department, and Hospital/Institute/DGHS 1. Audi Podern, Medical Oncology, Ren, Alm.		
With name, Designation, Department, and Hospital/Institute/DGHS 1. Audinew Podern, Medical encology, Ren, Alm, 2017125, Addinew Podern, Medical encology, Ren, Alm, 2017125, Addinew Podern, Medical encology, Ren, Alm, 2017125, Addinew Podern, Medical encology, Ren, Alm, 2017125, 20	. 1	it is certified that market survey has been done and found that no other
With name, Designation, Department, and Hospital/Institute/DGHS 1. Audinew Poderm, Medical Oncology, Ren, Alm, 2017125, Addinew Poderm, Medical Oncology, Ren, Alm, 2017125, 201		
With name, Designation, Department, and Hospital/Institute/DGHS 1. And Soferm, Medical Oncology, Ren, Alm, 2017-125, Addition Professor, Medical Oncology, Ren, Alm, 2017-125, Addition Dr. ATUL BATRA, MD, DM		
Amilias, Addinon Porderm, Medical Oncology, RCM, A11M, 2017-125, Addinon Porderm, Medical Oncology, RCM, A11M,		Signature of TSEC
Amilias, Addinon Pooferm, Medical oncology, RCM, A11M, 2017-125, Addinon Pooferm, Medical oncology, RCM, A11M, 2017-125	Wit	h name Designation Denomination of the contract of the contrac
A SOUTH WAINTERSTRUCK DATES AND DATE	**10	
अतिरियत आवार्य/Additional Professor रिकित्स अनुविज्ञान/Deptt. of Medical Oncology ंत्री, राज्य, राज्ये, केंबर अस्पताल/Dr. B.R.A., IRCF		अतिरियत आवार्य/Additional Professor शिकित्तः अधुद्यिज्ञान/Deptt. of Medical Oncology ंभै .स.अ., सं.से-कैसर अस्पताल/Dr. B.R.A., IRC)
The state of the s		Total and the second
हाँ, दीपम पुष्पम्, एम.डीबे.स्न Dr. DEEPAM PUSHPAM, M.D. DM		हाँ, दीपम पुष्पम्, एव.डी.,डीएन DEEPAM PUSHPAM, M.D., DM
Olegan Statem Salation form of Bedien Checkly	~	Delan and the state of the stat
THE TOTAL PROF. SAMEER BAKHSHI	र्थ सभीत	TOTOL SAMEER BAKHSHI

SERVIER INDIA PRIVATE LIMITED



Date: 15th November' 2023

To The Concerned

Subject: Confirming IKRIS Pharma network as authorised partner to provide access of Tibsovo (Ivosidenib) in India for Servier India Private Limited

Respected Sir/Mam,

This is to confirm that TIBSOVO (Ivosidenib) is prescription only medicine, belonging to the isocitrate dehydrogenase-1 (IDH1) inhibitor class of drugs. TIBSOVO is a registered trademark of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier. Tibsovo is available as a film-coated 250 mg tablet for oral administration, approved by USFDA since 2018. The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities. In this regard on behalf of Servier India, we confirm that IKRIS Pharma network is our authorised partner for providing access in India. A copy of the prescribing information is shared with the channel partner, treating oncologist and physician for their easy reference. In case of any additional information/ queries please do not hesitate to contact us.

Best regards,

July.

Dr. Poonam Gupta
Medical & Patient Affairs Director
Mobile +91 9920577551 – Phone (+91 22) 68 100 700
SERVIER INDIA Private Limited
1703, 17th Floor, Parinee Crescenzo, 'B' Wing, Plot Nos. C38 & 39, 'G' Block,
Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
www.servier.com



1703, 17th Floor, Parinee Crescenzo, 'B' Wing, Plot Nos. C-38 & 39, 'G' Blook, Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 – India. • Tel: +91 22 6810 0700. email: servier.india@servier.com
CIN: U52310MH1985PTC037001.

SERVIER INDIA PRIVATE LIMITED



Date: November 17, 2023

To Whomsoever it may Concern

Proprietary certificate

This is to certify and confirm IKRIS Pharma network as an authorised partner for Servier India Private Limited to provide access of Tibsovo (Ivosidenib), a proprietary product of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier.

TIBSOVO (Ivosidenib) is a prescription only medicine, belonging to the isocitrate dehydrogenase-1 (IDH1) inhibitor class of drugs. TIBSOVO is a registered trademark of Servier Pharmaceuticals LLC, a wholly owned, indirect subsidiary of Les Laboratoires Servier. Tibsovo is available as a film-coated 250 mg tablet for oral administration, approved by USFDA since 2018.

The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities. In this regard on behalf of Servier India, we confirm that IKRIS Pharma network is our authorised partner for providing access in India. A copy of the prescribing information is shared with the channel partner, treating oncologist and physician for their easy reference. In case of any additional information/ queries please do not hesitate to contact us.

Sincerely,

For SERVIER INDIA Private Limited

Dr. Pierre Perez Managing Director

